Innovation is in Multispan’s DNA
Dedicated to Advancing Drug Discovery Through Improved High Throughput Screening
Multispan believes innovation is a critical part of driving improvement across the drug discovery and development
pipeline — from promoting a deeper understanding of target biology, to identifying higher quality leads in less time, to
producing more physiologically relevant data for improved clinical translation. Our dedication to innovation is
evidenced through our unique approaches to recombinant expression of membrane proteins and novel assay
technologies which have led to over 30 patents.
MultiScreen™ β-Arrestin Sensor Technology
Multispan recognized the need for improved β-Arrestin screening assays and developed a novel HTS technology, MultiScreen β-Arrestin Sensor technology, that can assess β-Arrestin signaling of native GPCRs in recombinant or primary cells – a critical aspect for assessing receptor physiology.
Our assay kits, reagents and services based on MultiScreen™ β-Arrestin sensor technology enable researchers to examine unmodified GPCRs, including endogenously expressed GPCR targets, which provide more relevant data for
improved identification and optimization of qualified drug candidates.
Don’t let GPCR tagging bias your results. Find out how to unbias your GPCR signaling research.
Innovative Expression Technology
Multispan developed a proprietary technology to enable expression of GPCR proteins in mammalian cells at over a
million molecules per cell surface. High expressing cells (HEx™) can be developed into single cell clones and used as a
unique source of high quality GPCR proteins for variety of applications:
- Antibody generation using antigens with natural epitopes at high expression level
- Cell-based or membrane receptor binding assays to achieve high signal-to-noise ratio
- Cell-based functional assays for hard-to-express GPCRs from all 3 structurally distinctive GPCR families
- Structural studies as high-quality source of protein for crystallization